Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/26/22	SEK 7.660	-8.37%	1,865
21/26/21	SEK 8.360	-1.65%	16,299
20/26/20	SEK 8.500	+4.42%	4,360
19/26/19	SEK 8.140	+0.49%	10,358
16/26/16	SEK 8.100	+3.32%	4,782

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Annexin Pharmaceuticals AB

Company calendar

Delayed Nasdaq Stockholm 08:21:21 22/10/2026 pm IST			5-day change	1st Jan Change
7.660 ^SEK	-8.37%		-2.30%	-61.31%

03:37pm	Annexin Enrolls Last Patient in Mid-stage Trial of Eye Disease Drug Candidate	MT
25/09	12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

Market Cap	7.29Cr 73.68L 65.66L 60.79L 55.01L 1.04Cr 70Cr 1.05Cr 2.86Cr 37Cr 2.76Cr 2.71Cr 116.46Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	7.29Cr 73.68L 65.66L 60.79L 55.01L 1.04Cr 70Cr 1.05Cr 2.86Cr 37Cr 2.76Cr 2.71Cr 116.46Cr	EV / Sales 2026 *	1.57x	EV / Sales 2027 *	2.2x
Free-Float	54.78%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ANNX	Delayed
Deutsche Boerse AG	Q910	Delayed

03:37pm	Annexin Enrolls Last Patient in Mid-stage Trial of Eye Disease Drug Candidate	MT
25/09	12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
22/09	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
17/09	Annexin Pharmaceuticals Doses First Patient in Expanded Retinal Vein Occlusion Trial	MT
17/09	Annexin Pharmaceuticals AB Treats First Patient With Vanexin Following Anti-VEGF Injection In The NEXUS Study	CI
22/08	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
21/08	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT
21/08	Annexin Pharmaceuticals Advances the Nexus Study to Include Patients Who Received an Anti-Vegf Injection	CI
20/08	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV	CI
21/07	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
16/07	Calendar, Thursday, July 16	FW
23/06	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
15/06	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW

Annexin Pharmaceuticals AB Share Price

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news: Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

17/09	First patient treated with vanexin following anti-VEGF injection in the NEXUS study	AQ
10/09	Annexin Pharmaceuticals to Present at Investing in Life Science on September 22	AQ
21/08	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection	AQ
20/08	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV	AQ
21/07	Annexin updates on nine patients treated in NEXUS study	AQ

1 day	-8.37%
1 week	-2.30%
Current month	-13.15%
1 month	-24.53%
3 months	-37.72%
6 months	-49.27%
Current year	-61.31%

1 week	7.66	8.56
1 month	7.6	10.5
Current year	7.6	23.6
1 year	7.6	29.8
3 years	7.6	97.6
5 years	7.6	162
10 years	7.6	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	-8.37%	-2.30%	-70.31%	-88.11%	73.68L
WUXI APPTEC CO., LTD.	-4.10%	-8.35%	+38.48%	+66.99%	6.62TCr
ARGENX SE	-0.25%	+3.43%	+10.63%	+74.01%	5.52TCr
LONZA GROUP AG	+0.90%	+4.47%	+12.64%	+92.55%	5.28TCr
IQVIA HOLDINGS INC.	+0.62%	+2.80%	+27.89%	+51.66%	4.55TCr
BEONE MEDICINES AG	-1.49%	+1.82%	+21.48%	+125.74%	4.39TCr
REVOLUTION MEDICINES, INC.	-4.02%	-1.21%	+252.91%	+918.63%	4.16TCr
CELLTRION, INC.	-1.67%	+8.06%	+14.17%	+56.67%	3.4TCr
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-9.01%	+25.65%	-1.82%	2.58TCr
GENMAB A/S	+1.30%	+5.34%	+38.75%	+28.51%	2.35TCr
Average	-2.50%	+3.72%	+37.23%	+132.48%	3.89TCr
Weighted average by Cap.	-1.71%	+3.43%	+47.86%	+159.74%

	2026 *	2027 *
Net sales	4.63Cr 46.81L 41.71L 38.62L 34.95L 65.84L 44Cr 66.62L 1.82Cr 23Cr 1.76Cr 1.72Cr 74Cr	3.31Cr 33.46L 29.82L 27.61L 24.98L 47.07L 32Cr 47.63L 1.3Cr 17Cr 1.26Cr 1.23Cr 53Cr
Net income	-1.15Cr -11.63L -10.36L -10L -9L -16.35L -11Cr -16.55L -45.12L -5.77Cr -43.61L -42.7L -18Cr	-2.49Cr -25.17L -22.43L -20.77L -18.79L -35.41L -24Cr -35.83L -97.7L -12Cr -94.43L -92.46L -40Cr
Net Debt	-	-